|1.59||+0.19 / +13.57%|
As of Sep 26
|1.65||+0.06 / +3.77%|
The 3 analysts offering 12-month price forecasts for Cascadian Therapeutics Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 2.00. The median estimate represents a +88.68% increase from the last price of 1.59.
The current consensus among 4 polled investment analysts is to Buy stock in Cascadian Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.